Isabelle M Gorrillot, PhD

Co-founder, CEO

HO2Rx

Doylestown, United States

23 profile visits

At Ho2Rx we pioneer a game-changing therapy to safely and durably treat intractable chronic inflammatory diseases by targeting inflammation-damaged tissues.

My organisation

HO2Rx

SME

Doylestown, United States

HO2Rx is a preclinical biotech developing long-acting prodrug therapeutics to transform treatment of chronic inflammatory diseases (CID). Current therapies often fail due to toxicity, lack of tissue repair, and inability to prevent relapses that drive disease progression. Our HO2RT platform conjugates a selective anti-fibrotic and anti-inflammatory small molecule to a short biopolymer, enabling sustained restoration of tissue structures and functionalities that were damaged by recurrent inflammatory stimuli. In rodent models of periodontitis and IBD, just two subcutaneous injections of our lead candidate HO2RT-101 produced durable, scar-free tissue healing with excellent tolerability. We will first target periodontitis, a neglected disease affecting 1B people globally, where 70% of patients remain undertreated. Beyond its large market potential, periodontitis provides a rapid proof-of-relevance indication to validate our approach and expand to IBD and other chronic inflammatory disease segments. The program requires $30M (CHF 23.5M) to develop, with a projected $100B (~CHF78.4B) market opportunity by 2033. The additional upside of periodontitis stems from One Health veterinary applications to be out-licensed within 2 years thereby generating an early income stream.

About me

Dr. Isabelle M. Gorrillot brings more than 30 years of experience in biotechnology business development, licensing, and early-stage investment. In 2024, she co-founded HO2Rx, a pre-seed biotechnology venture, and serves as its fractional CEO, advancing therapeutics for chronic inflammatory diseases affecting millions of patients. The venture exemplifies her dual focus on scientific innovation and strategic entrepreneurship, combining breakthrough research with innovative corporate strategy to maximize impact and growth.

Dr. Gorrillot has contributed to numerous strategic partnerships, company-building initiatives, and scientific programs with significant potential deal value and health impact. She earned peer recognition for both her professional achievements and strong business ethics as Trustee of the Licensing Executives Society (LES) USA & Canada, and has led academia-industry partnering workshops. She reviews NIH SBIR/STTR grants, mentors early-career investigators and entrepreneurs, and advises the European Investment Bank (EIB) as a Technical Expert on scale-up investments.

A Pasteur-trained immunologist, Dr. Gorrillot’s strong scientific foundation has enabled her to translate a broad range of medical innovations into game-changing therapeutics across multiple disease areas. Outside her professional activities, she is an avid equestrian and horse lover, as well as an outdoor enthusiast who enjoys whitewater kayaking and hiking in the mountains.

Social media

Marketplace (2)

Project cooperation
Seeking scientific research partners for ERC/other grant applications
HO2Rx is looking for European ERC and other grant scientific partners to fund research projects (e.g., human and pet digestive microbiome, -omics, bioanalytics, Tox, stem cell). Attractive downstream opportunities (SAB, consulting, hiring).
Early
Other
Research
Technical
EU projects
Nano and Microtechnologies
Biotech, Pharma and Cosmetics
Partner looking for consortium
Author
Isabelle M Gorrillot, PhD
Co-founder, CEO at HO2Rx
Doylestown, United States
Project cooperation
€4.7M seed investment SAFE/Convertible
Seeking €4.7M seed investment SAFE/Convertible to fund the IND-enabling studies that would position our lead asset for clinical development by 1H2031.
Early
Other
Other
Biotech, Pharma and Cosmetics
Author
Isabelle M Gorrillot, PhD
Co-founder, CEO at HO2Rx
Doylestown, United States